Targets › FGG
1 program from 1 company in 1 trial: 1 Phase 3; Other; next expected readout Dec 2026.
Together with fibrinogen alpha (FGA) and fibrinogen beta (FGB), polymerizes to form an insoluble fibrin matrix. Has a major function in hemostasis as one of the primary components of blood clots. (UniProt, P02679)
Open in Phaseline: the race on FGG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Corza Medical | Fibrinogen, Human Fibrinogen exogenous protein | FGA, FGB, FGG | Phase 3 | Hemorrhage | Dec 2026 |
Hemorrhage (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.